CPH Group Expands Portfolio as Profit Slips but Dividend Held Steady

CPH Group AG Class A ( (CH:CPHN) ) has issued an update.

CPH Group AG reported 2025 net sales of CHF 334 million, up 3.3% year-on-year, but profitability declined as EBITDA fell 6.5% to CHF 50.3 million and net income dropped 32% to CHF 23.4 million amid currency headwinds, price pressure and overcapacity in pharmaceutical blister packaging. Despite the earnings decline and a slightly higher cost base after the Paper division spin-off, the board will propose an unchanged dividend of CHF 2.00 per share, signaling confidence in the group’s strategic direction and balance sheet strength.

The company pressed ahead with its expansion strategy, acquiring LOG Pharma and SiliCycle to broaden its pharmaceutical primary packaging and chromatography portfolios and reinforce positions in niche markets. Zeochem delivered record EBITDA and a margin above 20%, while Perlen Packaging grew sales but saw margins squeezed, prompting cost reductions, targeted investments and a focus on safeguarding profitability as management expects higher sales and earnings across both divisions in 2026.

The most recent analyst rating on (CH:CPHN) stock is a Hold with a CHF70.00 price target. To see the full list of analyst forecasts on CPH Group AG Class A stock, see the CH:CPHN Stock Forecast page.

More about CPH Group AG Class A

CPH Group AG is a Swiss industrial group operating through its Zeochem and Perlen Packaging divisions, focusing on specialty chemicals and pharmaceutical packaging. Zeochem produces molecular sieves, deuterated compounds and chromatography gels, while Perlen Packaging supplies blister films and primary packaging for medicines, serving global pharmaceutical and industrial markets.

Average Trading Volume: 1,359

Technical Sentiment Signal: Hold

Current Market Cap: CHF397.2M

Find detailed analytics on CPHN stock on TipRanks’ Stock Analysis page.